Self-administration of Subcutaneous Elranatamab in the Patients' Homes.

The goal of this open label, phase two, prospective, non-randomized, sponsor-initiated explorative trial is to test self-administration of subcutaneous Elranatamab in the patients' homes in patients with relapsed multiple myeloma exposed to at least one proteasome inhibitor, one IMID and one anti CD-38 antibody. The main question\[s\]it aims to answer are: * To evaluate the safety of self-administration of Elranatamab in the patients' own homes using registrations of occurrence of CRS, Immune effector cell-associated neurotoxicity syndrome (ICANS) and infections. * To evaluate the feasibility

Trial Details

NCT ID
NCT06015542
Phase
PHASE2
Sponsor
Thomas Lund
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Elranatamab
Locations (sample)
  • Odense, Denmark|55.39594,10.38831
  • Vejle, Denmark|55.70927,9.5357

Key Eligibility Criteria

  • ≥ 18 years of age at the time of signing the informed consent form.
  • Relapsed MM according to the IMWG criteria.
  • Measurable disease defined as: M-protein quantities ≥ 0.5 g/dL by serum protein electrophoresis (sPEP) or ≥ 200 mg/24-hour urine collection by urin…
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0, 1 or 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →